On Tuesday, DexCom Inc (DXCM) stock saw a decline, ending the day at $67.1 which represents a decrease of $-2.08 or -3.01% from the prior close of $69.18. The stock opened at $69 and touched a low of ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...
Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...
To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...
Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...
Valeo Financial Advisors LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 31.8% in the third ...
New York, New York-- (Newsfile Corp. - October 12, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and ...
(see more details here). DexCom, Inc. (NASDAQ:DXCM) is a specialty medical devices company that enables diabetics to monitor ...
Hosted on MSN6d
Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's likeDexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback